Zobrazeno 1 - 10 of 42 pro vyhledávání: '"Daniel Primo"'
2
Improving NK cell function in multiple myeloma with NKTR-255, a novel polymer-conjugated human IL-15
Autor: Rafael Alonso Fernandez, Jessica Encinas Mayoral, Laetitia Pierre-Louis, Yao Yao, Yan Xu, Shidai Mu, Joaquin Martinez-Lopez, Daniel Primo, Takahiro Miyazaki, Rao Prabhala, Kenneth C. Anderson, Willem W. Overwijk, Nikhil C. Munshi, Mariateresa Fulciniti
Publikováno v: Blood Advances. 7:9-19
Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that enables tumor development. One of the mechanisms of immune evasion used by MM cells is the inhibition of natural killer (NK) cell effector functions; thus, the resto
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3abc201e043234417ad852889fbdfff0
https://doi.org/10.1182/bloodadvances.2022007985
Zobrazit plný text záznamu
3
Akademický článek
Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair
Autor: Ana-Alicia López-Iglesias, Ana B. Herrero, Marta Chesi, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Irena Misiewicz-Krzeminska, Dalia Quwaider, Montserrat Martín-Sánchez, Daniel Primo, Teresa Paíno, P. Leif Bergsagel, Thomas Mehrling, Marcos González-Díaz, Jesús F. San-Miguel, María-Victoria Mateos, Norma C. Gutiérrez, Mercedes Garayoa, Enrique M. Ocio
Publikováno v: Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-14 (2017)
Abstract Background Despite recent advances in the treatment of multiple myeloma (MM), the prognosis of most patients remains poor, and resistance to traditional and new drugs frequently occurs. EDO-S101 is a novel therapeutic agent conceived as the
Externí odkaz: https://doaj.org/article/bfebf6dd497c42b797a071d86cc0e1d4
Zobrazit plný text záznamu
4
Akademický článek
Ruxolitinib in combination with prednisone and nilotinib exhibit synergistic effects in human cells lines and primary cells from myeloproliferative neoplasms
Autor: Alicia Arenas Cortés, Rosa Ayala Diaz, Pilar Hernández-Campo, Julián Gorrochategui, Daniel Primo, Alicia Robles, María Luz Morales, Joan Ballesteros, Inmaculada Rapado, Miguel Gallardo, María Linares, Joaquín Martínez-López
Publikováno v: Haematologica, Vol 104, Iss 5 (2019)
Ruxolitinib is the front-line non-palliative treatment for myelofibrosis (MF). However, a significant number of patients lose or present suboptimal response, are resistant or have unacceptable toxicity. In an attempt to improve response and avoid the
Externí odkaz: https://doaj.org/article/aded39ba73634bc3a45a4b798400a755
Zobrazit plný text záznamu
5
Akademický článek
DIFFERENCES IN EX-VIVO CHEMOSENSITIVITY TO ANTHRACYCLINES IN FIRST LINE ACUTE MYELOID LEUKEMIA
Autor: Juan Eduardo Megias-Vericat, David Martínez-Cuadrón, Joaquin Martínez López, Juan Miguel Bergua, Mar Tormo, Josefina Serrano, Ataulfo González, Jaime Pérez de Oteyza, Susana Vives, Belen Vidriales, Pilar Herrera, Juan Antonio Vera, Aurelio López Martínez, Adolfo De la Fuente, María Lourdes Amador, José Ángel Hernández-Rivas, María Ángeles Fernández, Carlos Javier Cerveró, Daniel Morillo, Pilar Hernández Campo, Julián Gorrochategui, Daniel Primo, José Luis Rojas, Margarita Guenova, Joan Ballesteros, Miguel Ángel Sanz, Pau Montesinos
Publikováno v: Mediterranean Journal of Hematology and Infectious Diseases, Vol 11, Iss 1, Pp e2019016-e2019016 (2019)
BACKGROUND: Induction schedules in acute myeloid leukemia (AML) are based on combinations of cytarabine and anthracyclines. The choice of the anthracycline employed has been widely studied in multiple clinical trials showing similar complete remissio
Externí odkaz: https://doaj.org/article/81b4fa5b2a224f32948fabdc5eced125
Zobrazit plný text záznamu
9
P-003: Improving NK cell function in Multiple Myeloma with NKTR-255, a novel polymer-conjugated human IL-15
Autor: Yan Xu, Nikhil C. Munshi, Takahiro Miyazaki, Kenneth C. Anderson, Rao Prabhala, Shidai Mu, Laetitia Pierre-Louis, Rafael Alonso Fernández, Daniel Primo, Willem Overwijk, Mariateresa Fulciniti, Joaquin Martinez-Lopez
Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S40-S41
Background Multiple myeloma (MM) is characterized by an immunosuppressive microenvironment that enables tumor development. One of the mechanisms of immune evasion used by MM cells is the inhibition of NK cell effector functions; thus, the restoration
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::afa6771a7080df6c7818e348664932f7
https://doi.org/10.1016/s2152-2650(21)02137-6
Zobrazit plný text záznamu
10
763 Expanded and activated TILs kill tumor cells enabling IO compound assays
Autor: Elena Sevillano Fernandez, Arántzazu Barquín García, Daniel Primo, Jesus Garcia Donas Jimenez, Monica Yagüe, Sergio Ruiz Llorente, Joan Ballesteros, Juan Francisco Rodriguez, Verónica García Navas, Paula Comune Pennacchi, Paloma Navarro
Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Background The Tumor Microenvironment (TME) has a key role in solid tumor therapy screening. We have developed a 3D ex vivo immunosuppressive assay mimicking the TME. It enables both allogenic & autologous tumor lysis by expanded Tumor Infiltrate Lym
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b99d57b36480a440148b12337b75a363
https://doi.org/10.1136/jitc-2020-sitc2020.0763
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje